Evidence map›Paper›PMID 39731082›Full record

ArticleBMC ophthalmology2024

Early response of anti-vascular endothelial growth factor (anti-VEGF) in diabetic macular edema (DME) management: microperimetry and optical coherence tomography (OCT) findings: a pilot study at national eye center of third world country.

Grimaldi Ihsan, Ameliza Kwartika, Made Indra Widyanatha, Rova Virgana, Erwin Iskandar, Arief Sjamsulaksan Kartasasmita

Abstract read
In one paragraph

Article in BMC ophthalmology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Grimaldi IhsanVitreoretina Department National Eye Center Cicendo Eye Hospital, Bandung, Indonesia. grimaldi@unpad.ac.id.
Ameliza KwartikaVitreoretina Department National Eye Center Cicendo Eye Hospital, Bandung, Indonesia. amel.matagama@gmail.com.
Made Indra WidyanathaVitreoretina Department National Eye Center Cicendo Eye Hospital, Bandung, Indonesia.
Rova VirganaVitreoretina Department National Eye Center Cicendo Eye Hospital, Bandung, Indonesia.
Erwin IskandarVitreoretina Department National Eye Center Cicendo Eye Hospital, Bandung, Indonesia.
Arief Sjamsulaksan KartasasmitaVitreoretina Department National Eye Center Cicendo Eye Hospital, Bandung, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate early response of retinal sensitivity (RS) and retinal morphology in diabetic macular edema (DME) patients after intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment.

methodsSixteen eyes of 12 DME patients were included in this study conducted prospectively. All eyes underwent functional and morphologic examination of the macular area using microperimetry and optical coherence tomography (OCT) before and after intravitreal anti-VEGF injection. To determine significant differences between the values, paired t test was used. A correlation between CMT and RS was made using Spearman's test.

resultsPatients were evaluated at baseline, one week and one month after injection. The central macular thickness (CMT) decreased significantly from 449.33 ± 100.79 μm to 427.94 ± 85.76 μm to 357.93 ± 75.92 μm. The RS improved significantly from 7.94 ± 6.43 dB to 11.09 ± 7.42 dB at one week and to 14.22 ± 7.66 dB at one month after treatment. The CMT was significant negatively correlated to RS (r=-0.259, p = < 0.001), with decay of 0.025 dB for every 1 μm increase of CMT.

conclusionsRetinal thickening due to DME can be adequately quantified using OCT, while microperimetry can offer information about retinal sensitivity in the exact location. Therefore, microperimetry can be a useful tool in predicting the functional outcome and determining the efficacy of anti-VEGF treatment for DME patients.

Indexed as

Angiogenesis InhibitorsDiabetic RetinopathyIntravitreal InjectionsMacular EdemaRanibizumabTomography, Optical CoherenceVascular Endothelial Growth Factor AVisual AcuityVisual Field TestsAgedBevacizumabFemaleHumansMaleMiddle AgedPilot ProjectsAngiogenesis InhibitorsBevacizumabRanibizumabVascular Endothelial Growth Factor AAnti-VEGF responseDiabetic macular edemaMacular thicknessMicroperimetryOptical coherence tomography (OCT)Retinal sensitivity

Identifiers

PMID39731082
PMCPMC11674592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.